This site is intended for
US Healthcare Professionals only.

Symdeko

FOR PATIENTS WITH CF AGED 6 YEARS AND OLDER WITH AT LEAST ONE MUTATION THAT IS RESPONSIVE TO SYMDEKO1

Check Treatment Eligibility

Enter your patient's mutations below

Enter your patient’s mutations below to see if they are eligible for SYMDEKO.

SYMDEKO is indicated for the treatment of cystic fibrosis (CF) in patients age 6 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence.

SYMDEKO is indicated for the treatment of cystic fibrosis (CF) in patients age 6 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence.

Mutation 1
(optional) (optional)
Mutation 2 (optional)
Eligible

Mutation(s) not recognized. Please check to see if they were entered correctly.

Results

Learn how to enter 2 or more mutations